Sign in
WithdrawnPhase 4

Role Of Sensitivity to neuroEndocrine Systems in Social Decisions

Key facts

Who runs it
University of North Carolina, Chapel Hill
Where
Chapel Hill, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 4
Started
Jul 2024
Ended
Jul 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Hydrocortisone
  • Yohimbine
  • Placebo
Record updated
5 June 2024
Why it stopped
Changed study design and it is no longer a clinical trial.

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Borderline Personality Disorder (BPD) group:
  • Score of 38 or higher on PAI-BOR
  • Participants in the BPD group will be primarily recruited from the two DEPENd lab studies that maintain large samples of BPD participants. To ensure maximal similarity between BPD participants recruited from other DEPENd lab studies and BPD participants recruited through other recruitment sources, the investigators will use the same criteria for the BPD group in the ROSES study as the criteria used in the other DEPENd lab studies. BPD participants in the two DEPENd lab studies from which the investigators will be recruiting must meet the following criteria:; 3+ BPD symptoms, one of which must be affective instability, per clinical interview; Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST); Matched Control (MC) group:
  • Score of 12 or lower on PAI-BOR
  • Score below 50th percentile on WHODAS; Combined Inclusion Criteria:
  • Ages 18-45
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Willingness to participate in all components of the study
  • Access to necessary resources for participating in the virtual Session 1 (i.e., computer, smartphone, internet access)
  • Participants must be able to speak, understand and read English
  • Participants must have at least 20/40 visual acuity (correct or uncorrected)

Who cannot take part

  • Current use of medications that interact adversely with yohimbine; Iobenguane radiopharmaceutical products
  • Current use of medications that interact adversely with hydrocortisone; Aldesleukin; Bacillus Calmette-Guérin (BCG) Products; Cladribine; Dengue Tetravalent Vaccine; Desmopressin; Indium 111 Capromab Pendetide; Macimorelin; Mifamurtide; MiFEPRIStone; Natalizumab; Pimecrolimus:; Ruxolitinib (Topical); Tacrolimus (Topical); Talimogene Laherparepvec; Tertomotide; Phenytoin; Rifampin; Troleandomycin; Ketoconazole; High-dose aspirin (>30 mg/kg/day)
  • Given a live vaccine within 2 weeks of completing Visit 1. Recent administration of the following vaccines are specifically contraindicated for hydrocortisone:; Typhoid Vaccine; Yellow Fever Vaccine; Poliovirus Vaccine (Live/Trivalent/Oral); Rubella- or Varicella-Containing Live Vaccines
  • Contraindicated medical conditions of yohimbine; Renal dysfunction; Hepatic dysfunction; Heart failure; Psychotic Disorder or psychosis; Hypotension; Diabetes; Heart disease; Kidney disease; Liver disease; Nervous disorder; Gastric ulcer; Duodenal ulcer
  • Contraindicated medical conditions of hydrocortisone; Hypersensitivity to hydrocortisone or any component of the formulation; Systemic fungal infections; Latent Tuberculosis, Tuberculosis reactivity, active Tuberculosis; Cardiovascular disease; Diabetes; Gastrointestinal diseases; Diverticulitis ii. Fresh intestinal anastomoses iii. Active or latent peptic ulcer iv. Ulcerative colitis v. Abscess vi. Renal insufficiency vii. Other pyogenic infection g. Hepatic impairment h. Kidney impairment i. Myasthenia gravis j. Osteoporosis k. Pheochromocytoma l. Seizure disorders m. Septic shock or sepsis syndrome n. Systemic sclerosis o. Thyroid disease p. Strongyloides (threadworm) infestation q. Ocular herpes simplex r. Hypertension
  • Have a current infection
  • History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence
  • Family history of Bipolar I disorder in a first degree relative
  • Pregnancy
  • Individuals lactating
  • Recent antihypertensive agents

Where in United States

  • University of North Carolina at Chapel HillChapel Hill, United States

About the trial

What the trial wants to find out

The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making.

Read full original descriptionShow less

This study has two components. First, there will be an online session that participants complete to consent into the study, complete self-report surveys and a cognitive assessment, and confirm their eligibility for the second part of the study. If eligible to continue, participants will complete one in-person experiment session, during which they will complete self-report measures and a decision-making task. During the in-person session, participants will be randomly assigned (like flipping a coin) to ingest either a placebo (non-active) or the combination of hydrocortisone and yohimbine.

The 2 groups in the trial

  • Hydrocortisone + YohimbineTreatment being tested

    Participants will ingest hydrocortisone and yohimbine during Session 2 approximately 10 minutes into the session.

    Treatment: Hydrocortisone and Yohimbine

  • Placebo + PlaceboPlacebo, for comparison

    Participants will orally ingest two placebos during Session 2 approximately 10 minutes into the session.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
5 June 2024